Cargando…

In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice

Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-co...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhat, Zahid Rafiq, Kumar, Manvendra, Sharma, Nisha, Yadav, Umesh Prasad, Singh, Tashvinder, Joshi, Gaurav, Pujala, Brahmam, Raja, Mohd, Chatterjee, Joydeep, Tikoo, Kulbhushan, Singh, Sandeep, Kumar, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457798/
https://www.ncbi.nlm.nih.gov/pubmed/36080307
http://dx.doi.org/10.3390/molecules27175540
_version_ 1784786144662126592
author Bhat, Zahid Rafiq
Kumar, Manvendra
Sharma, Nisha
Yadav, Umesh Prasad
Singh, Tashvinder
Joshi, Gaurav
Pujala, Brahmam
Raja, Mohd
Chatterjee, Joydeep
Tikoo, Kulbhushan
Singh, Sandeep
Kumar, Raj
author_facet Bhat, Zahid Rafiq
Kumar, Manvendra
Sharma, Nisha
Yadav, Umesh Prasad
Singh, Tashvinder
Joshi, Gaurav
Pujala, Brahmam
Raja, Mohd
Chatterjee, Joydeep
Tikoo, Kulbhushan
Singh, Sandeep
Kumar, Raj
author_sort Bhat, Zahid Rafiq
collection PubMed
description Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-covalent imidazo[1,2-a]quinoxaline-based EGFR inhibitor (6b), which showed promising inhibitory activity against the gefitinib-resistant H1975(L858R/T790M) lung cancer cell line. In the present study, we further explored the 6b compound in vivo by employing the A549-induced xenograft model in nude mice. The results indicate that the administration of the 6b compound significantly abolished the growth of the tumor in the A549 xenograft nude mice. Whereas the control mice bearing tumors displayed a declining trend in the survival curve, treatment with the 6b compound improved the survival profile of mice. Moreover, the histological examination showed the cancer cell cytotoxicity of the 6b compound was characterized by cytoplasmic destruction observed in the stained section of the tumor tissues of treated mice. The immunoblotting and qPCR results further signified that 6b inhibited EGFR in tissue samples and consequently altered the downstream pathways mediated by EGFR, leading to a reduction in cancer growth. Therefore, the in vivo findings were in corroboration with the in vitro results, suggesting that 6b possessed potential anticancer activity against EGFR-dependent lung cancer. 6b also exhibited good stability in human and mouse liver microsomes.
format Online
Article
Text
id pubmed-9457798
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94577982022-09-09 In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice Bhat, Zahid Rafiq Kumar, Manvendra Sharma, Nisha Yadav, Umesh Prasad Singh, Tashvinder Joshi, Gaurav Pujala, Brahmam Raja, Mohd Chatterjee, Joydeep Tikoo, Kulbhushan Singh, Sandeep Kumar, Raj Molecules Article Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-covalent imidazo[1,2-a]quinoxaline-based EGFR inhibitor (6b), which showed promising inhibitory activity against the gefitinib-resistant H1975(L858R/T790M) lung cancer cell line. In the present study, we further explored the 6b compound in vivo by employing the A549-induced xenograft model in nude mice. The results indicate that the administration of the 6b compound significantly abolished the growth of the tumor in the A549 xenograft nude mice. Whereas the control mice bearing tumors displayed a declining trend in the survival curve, treatment with the 6b compound improved the survival profile of mice. Moreover, the histological examination showed the cancer cell cytotoxicity of the 6b compound was characterized by cytoplasmic destruction observed in the stained section of the tumor tissues of treated mice. The immunoblotting and qPCR results further signified that 6b inhibited EGFR in tissue samples and consequently altered the downstream pathways mediated by EGFR, leading to a reduction in cancer growth. Therefore, the in vivo findings were in corroboration with the in vitro results, suggesting that 6b possessed potential anticancer activity against EGFR-dependent lung cancer. 6b also exhibited good stability in human and mouse liver microsomes. MDPI 2022-08-28 /pmc/articles/PMC9457798/ /pubmed/36080307 http://dx.doi.org/10.3390/molecules27175540 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bhat, Zahid Rafiq
Kumar, Manvendra
Sharma, Nisha
Yadav, Umesh Prasad
Singh, Tashvinder
Joshi, Gaurav
Pujala, Brahmam
Raja, Mohd
Chatterjee, Joydeep
Tikoo, Kulbhushan
Singh, Sandeep
Kumar, Raj
In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice
title In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice
title_full In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice
title_fullStr In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice
title_full_unstemmed In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice
title_short In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice
title_sort in vivo anticancer evaluation of 6b, a non-covalent imidazo[1,2-a]quinoxaline-based epidermal growth factor receptor inhibitor against human xenograft tumor in nude mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457798/
https://www.ncbi.nlm.nih.gov/pubmed/36080307
http://dx.doi.org/10.3390/molecules27175540
work_keys_str_mv AT bhatzahidrafiq invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT kumarmanvendra invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT sharmanisha invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT yadavumeshprasad invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT singhtashvinder invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT joshigaurav invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT pujalabrahmam invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT rajamohd invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT chatterjeejoydeep invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT tikookulbhushan invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT singhsandeep invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice
AT kumarraj invivoanticancerevaluationof6banoncovalentimidazo12aquinoxalinebasedepidermalgrowthfactorreceptorinhibitoragainsthumanxenografttumorinnudemice